Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStill hungry on day 1 of Mounjaro? That's not a sign something has gone wrong. The 2.5mg starting dose is designed to let your body adjust to the medicine, not to suppress your appetite straight away — most people notice little to no change in hunger during the first week or two. Mounjaro (tirzepatide) is a prescription-only medicine that works by activating two gut-hormone receptors, and that process builds gradually. Your hunger on day 1 is entirely expected, and understanding why can save a lot of unnecessary worry.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the most common misconception, and it causes real frustration. People start their first pen, eat their usual lunch, feel exactly as hungry as always, and quietly wonder whether they've been sold something ineffective. They haven't.
The 2.5mg dose exists for one reason: to let your gut, liver and brain adapt to a new hormone signal before that signal is turned up. Nausea, vomiting and gastrointestinal discomfort are the most common reasons people stop tirzepatide early, and the graduated dose schedule exists precisely to reduce that risk. The NHS tirzepatide medicines page explains this clearly, treatment begins at 2.5mg and is titrated upward by the prescriber, typically in four-week steps.
Appetite suppression is a downstream effect of the GIP and GLP-1 receptor activation that tirzepatide produces. That effect is dose-dependent and cumulative. At 2.5mg, many people feel nothing. Some notice a very slight reduction in interest in food toward the end of the first week. A minority feel nauseous before they feel any appetite change at all. All of these are normal. If you're reading about day 1 and wondering whether the experience gets clearer over the following days, our page on what to expect on your first day on Mounjaro covers the pattern in more detail.
Tirzepatide mimics two gut hormones (GIP and GLP-1) that are released naturally after eating. These hormones signal fullness to the brain, slow down how quickly your stomach empties, and affect insulin and glucagon release. At therapeutic doses, this multi-pathway action is what leads to the appetite and weight changes seen in clinical trials: in the SURMOUNT-1 trial, participants lost an average of around 20–21% of body weight over 72 weeks at the highest dose, as reported in the New England Journal of Medicine.
But none of that happens on day 1 at 2.5mg. The medicine needs time to reach a steady concentration in your system, it has a half-life of roughly five days, which means blood levels are still climbing across the first few weeks even on a fixed dose. Your hunger signals are running on the biology they've always used. A single injection hasn't rewritten them yet.
Think of it like this: the pen sitting in your fridge door after your first injection has started something, not finished it. The full picture of how hunger changes as doses increase is covered on our guide to ongoing hunger on Mounjaro, which is useful reading for the weeks ahead.
Because appetite suppression isn't yet your ally, the early weeks on Mounjaro are a good time to lean on what you can control. The NHS and clinical guidance consistently point to a few practical priorities: adequate protein at each meal (it's the most satiating macronutrient), enough dietary fibre, and staying well hydrated. These matter throughout treatment but are especially useful before the medicine starts doing more of the heavy lifting.
If you want a structured look at what eating patterns tend to work well alongside tirzepatide, our guide to eating on Mounjaro pulls together the practical detail. The short version: focus on volume-to-calorie ratio and protein, keep ultra-processed foods moderate, and don't try to eat very little too soon, that approach tends to lead to energy crashes rather than sustainable reduction.
One thing to avoid on day 1 is interpreting hunger as failure and overcompensating. Severe restriction when the medicine isn't yet reducing appetite tends to backfire, and it isn't what the prescribing process assumes you'll do. The licensed recommendation is a reduced-calorie diet and increased activity alongside treatment, not a crash approach from the first injection. If you have specific questions about titration or what to expect at each stage, the right place to raise them is with your prescriber, not a forum or a general search. Our full Mounjaro information page sets out what the clinical programme looks like from start to finish.
Feeling hungry on day 1 is normal. Feeling persistently hungry weeks into treatment at a higher dose is a different question, and one worth raising. Some people find appetite suppression arrives clearly at 5mg or 7.5mg. For others, it takes longer. The pattern matters more than any single day.
What always warrants a call rather than a wait: if hunger is accompanied by any unusual symptoms, if you're struggling significantly with side effects at any dose, or if you're unsure whether your response is typical. Tirzepatide is a prescription-only medicine, and the clinical review process exists for exactly these situations. If you're exploring treatment options more broadly, you can read about our prescriber-reviewed weight-loss treatments to understand how the consultation and ongoing support works at nume.
For those who are a few days in and still finding hunger unchanged, the experience is common enough that we've addressed it directly. Day 2 and day 3 questions follow a similar pattern, and if you're still not noticing any appetite change by the third day, our page on why you may still feel hungry on day 3 of Mounjaro addresses exactly that point, see also what to expect on day 2 if you're still hungry for the next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.